These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1018 related articles for article (PubMed ID: 22385403)

  • 1. Biologic rheumatoid arthritis therapies: do we need more comparative effectiveness data?
    Levesque MC
    BioDrugs; 2012 Apr; 26(2):65-70. PubMed ID: 22385403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Summary of AHRQ's comparative effectiveness review of drug therapy for rheumatoid arthritis (RA) in adults--an update.
    Singh JA; Cameron DR
    J Manag Care Pharm; 2012 May; 18(4 Supp C):S1-18. PubMed ID: 22656072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessing the cost-effectiveness of biologic agents for the management of moderate-to-severe rheumatoid arthritis in anti-TNF inadequate responders in Italy: a modelling approach.
    Cimmino MA; Leardini G; Salaffi F; Intorcia M; Bellatreccia A; Dupont D; Beresniak A
    Clin Exp Rheumatol; 2011; 29(4):633-41. PubMed ID: 21813056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis: A network meta-analysis.
    Hazlewood GS; Barnabe C; Tomlinson G; Marshall D; Devoe DJ; Bombardier C
    Cochrane Database Syst Rev; 2016 Aug; 2016(8):CD010227. PubMed ID: 27571502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronological changes in baseline disease activity of patients with rheumatoid arthritis who received biologic DMARDs between 2003 and 2012.
    Sato E; Tanaka E; Ochiai M; Shimizu Y; Kobayashi A; Shidara K; Hoshi D; Sugimoto N; Inoue E; Seto Y; Nakajima A; Taniguchi A; Momohara S; Yamanaka H
    Mod Rheumatol; 2015 May; 25(3):350-7. PubMed ID: 25619283
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of biologic therapies in the treatment of rheumatoid arthritis.
    Wang D; Li Y; Liu Y; Shi G
    Curr Pharm Biotechnol; 2014; 15(6):542-8. PubMed ID: 25213363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The issue of comparators in economic evaluations of biologic response modifiers in rheumatoid arthritis.
    Tsao NW; Bansback NJ; Shojania K; Marra CA
    Best Pract Res Clin Rheumatol; 2012 Oct; 26(5):659-76. PubMed ID: 23218430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is it possible to withdraw biologics from therapy in rheumatoid arthritis?
    Tanaka Y; Hirata S
    Clin Ther; 2013 Dec; 35(12):2028-35. PubMed ID: 24290736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative cancer risk associated with methotrexate, other non-biologic and biologic disease-modifying anti-rheumatic drugs.
    Solomon DH; Kremer JM; Fisher M; Curtis JR; Furer V; Harrold LR; Hochberg MC; Reed G; Tsao P; Greenberg JD
    Semin Arthritis Rheum; 2014 Feb; 43(4):489-97. PubMed ID: 24012043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Summary of AHRQ's Comparative Effectiveness Review of Disease-Modifying Antirheumatic Drugs for Children with Juvenile Idiopathic Arthritis.
    McMahan R; Balfe LM; Greene L
    J Manag Care Pharm; 2012; 18(1 Suppl B):1-16. PubMed ID: 22376227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biologic agents in rheumatoid arthritis: an update for managed care professionals.
    Agarwal SK
    J Manag Care Pharm; 2011; 17(9 Suppl B):S14-8. PubMed ID: 22073935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world utilization of DMARDs and biologics in rheumatoid arthritis: the RADIUS (Rheumatoid Arthritis Disease-Modifying Anti-Rheumatic Drug Intervention and Utilization Study) study.
    Gibofsky A; Palmer WR; Goldman JA; Lautzenheiser RL; Markenson JA; Weaver A; Schiff MH; Keystone EC; Paulus HE; Harrison MJ; Whitmore JB; Leff JA
    Curr Med Res Opin; 2006 Jan; 22(1):169-83. PubMed ID: 16393443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Update on methotrexate as the anchor drug for rheumatoid arthritis.
    Pincus T; Gibson KA; Castrejón I
    Bull Hosp Jt Dis (2013); 2013; 71 Suppl 1():S9-19. PubMed ID: 24219036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative effectiveness of treatment options after conventional DMARDs failure in rheumatoid arthritis.
    Sung YK; Cho SK; Kim D; Choi CB; Won S; Bang SY; Cha HS; Choe JY; Chung WT; Hong SJ; Jun JB; Kim HA; Kim J; Kim SK; Kim TH; Lee HS; Lee J; Lee J; Lee SS; Lee SW; Lee YA; Nah SS; Suh CH; Yoo DH; Yoon BY; Bae SC;
    Rheumatol Int; 2017 Jun; 37(6):975-982. PubMed ID: 28132102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mixed treatment comparison of the treatment discontinuations of biologic disease-modifying antirheumatic drugs in adults with rheumatoid arthritis.
    Desai RJ; Hansen RA; Rao JK; Wilkins TM; Harden EA; Yuen A; Jonas DE; Roubey R; Jonas B; Gartlehner G; Lux L; Donahue KE
    Ann Pharmacother; 2012 Nov; 46(11):1491-505. PubMed ID: 23092868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Refining a Claims-based Algorithm to Estimate Biologic Medication Effectiveness and Cost per Effectively Treated Patient with Rheumatoid Arthritis.
    Popp RA; Rascati K; Davis M; Patel U
    Pharmacotherapy; 2018 Feb; 38(2):172-180. PubMed ID: 29197108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis.
    Donahue KE; Gartlehner G; Jonas DE; Lux LJ; Thieda P; Jonas BL; Hansen RA; Morgan LC; Lohr KN
    Ann Intern Med; 2008 Jan; 148(2):124-34. PubMed ID: 18025440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Are All Biologics the Same? Optimal Treatment Strategies for Patients With Early Rheumatoid Arthritis: Systematic Review and Indirect Pairwise Meta-Analysis.
    Albert DA
    J Clin Rheumatol; 2015 Dec; 21(8):398-404. PubMed ID: 26226612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of drug and administrative costs allowed by U.S. Private and public third-party payers for 3 intravenous biologic agents for rheumatoid arthritis.
    Wong BJ; Cifaldi MA; Roy S; Skonieczny DC; Stavrakas S
    J Manag Care Pharm; 2011 May; 17(4):313-20. PubMed ID: 21534642
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost per response for abatacept versus adalimumab in patients with seropositive, erosive early rheumatoid arthritis in the US, Germany, Spain, and Canada.
    Foo J; Morel C; Bergman M; Baerwald C; Rodriguez-Heredia JM; Marshall A; Polanco-Sánchez C; Postema R
    Rheumatol Int; 2019 Sep; 39(9):1621-1630. PubMed ID: 31240388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 51.